Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07120152) titled 'A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease' on Aug. 6.
Study Type: Observational
Primary Sponsor: Vicky Steyfkens
Condition:
IBD - Inflammatory Bowel Disease
RA - Rheumatoid Arthritis
Intervention:
Drug: Subcutaneous infliximab CT-P13 Remsima(R)SC
Recruitment Status: Not recruiting
Date of First Enrollment: September 1, 2025
Target Sample Size: 439
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07120152
Published by HT Digital Content Services with permission from Health Daily Digest....